C. Villarreal Garza

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

David Miles, Eva Ciruelos, Fabio Puglisi, Tamar Peretz‐Yablonski et autres

BACKGROUND: The phase III CLinical Evaluation Of Pertuzumab And TRAstuzumab (CLEOPATRA) trial established the combination of pertuzumab, trastuzumab and docetaxel as standard first-line therapy for human epidermal growth factor receptor 2 (HER2)-positive locally recurrent/metastatic breast cancer (LR/mBC). The multicentre single-arm PERtUzumab global …

gb, es, de, it, il, fr, ua, pl, Maroc, us, ch (code pays fourni par la source)

8P Knowledge, practice and attitudes of physicians in low- and middle-income countries (LMIC) on fertility and pregnancy-related issues in young breast cancer patients

S. Zeb Khan, C. Villarreal Garza, Bhawna Sirohi, Noam Pondé et autres

mx, in, br, iq, be, rs, Kenya, Éthiopie, République démocratique du Congo, ar, ro, ca, it (code pays fourni par la source)

“Joven y Fuerte Metastásico”: Integrative Oncology Intervention for Metastatic Breast Cancer Patients

A. Platas de la Mora, C.L. Gálvez Hernández, A.L. Platas de la Mora, A. Fonseca Perezamador et autres

Background and context: Breast cancer (BC) patients in Mexico are frequently diagnosed at advanced stages, with stages III or IV comprising up to 60%. Advanced BC (ABC) patients face distinct practical and emotional challenges and are recognized to be vulnerable to additional …

mx (code pays fourni par la source)

P286 Single dose with IORT for breast cancer: initial experience with Latin American women

Juan Enrique Bargalló Rocha, Christian Haydeé Flores Balcázar, V.M. Pérez Sánchez, J. Corona et autres